BioSpace News Archive

Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, today announces that management will participate in the virtual 40th Annual J.P. Morgan Healthcare Conference.

Zynerba Pharmaceuticals, Inc. announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present during the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022.

First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), today announced that it has completed enrollment for Part 2 of the RESERVOIR Phase 2 trial evaluating FW-COV as an outpatient treatment for COVID-19-related gastrointestinal (GI) infections.

Centene Corporation (NYSE: CNC) today announced that Jim Murray has been appointed as Chief Transformation Officer.

Curis, Inc. today announced positive updated clinical data from the ongoing open label Phase 1/2 dose escalation and expansion study of CA-4948.

Synairgen plc, the respiratory company developing SNG001 for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs, announces a partnership with global experts in strategic engagement and commercialisation, Ashfield Engage.

Honor Recognizes Companies Advancing Innovative Solutions to Improve Women’s Health and Safety in Emerging Markets.

Potential one-time gene therapy for the treatment of Duchenne includes a novel, optimized microdystrophin transgene and REGENXBIO’s proprietary NAV ® AAV8 vector.

Anebulo Pharmaceuticals, Inc. announced today that it has appointed Scott L. Anderson as Head of Investor Relations and Public Relations, effective immediately.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, provided an update today from the ongoing Phase 1 clinical trial of INB-200, an autologous DeltEx drug resistant immunotherapy (DRI).